Stay updated with breaking news from Toronto Memory Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement,
/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3...
STOCKHOLM, Nov. 30, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory
The drug lecanemab slowed the rate of cognitive decline among people with early Alzheimer's disease by 27 per cent, compared with placebo infusions, but some question if its potential safety concerns outweigh any benefits
Eisai has presented and published full data from the Phase 3 clinical trial for its Alzheimer’s disease drug lecanemab, with results showing a statistically significant slowing decline associated with the neurodegenerative disorder. While an accelerated approval decision is expected in early 2023, the latest trial data are key because they represent the confirmatory study that could support an application for full FDA approval.